Medpace (NASDAQ:MEDP) CEO Sells $3,083,825.36 in Stock

by · The Cerbat Gem

Medpace Holdings, Inc. (NASDAQ:MEDP – Get Free Report) CEO August Troendle sold 5,128 shares of the stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $601.37, for a total transaction of $3,083,825.36. Following the completion of the transaction, the chief executive officer owned 914,162 shares of the company’s stock, valued at $549,749,601.94. This trade represents a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Medpace Price Performance

Shares of MEDP traded down $1.23 during mid-day trading on Friday, hitting $590.09. The company’s stock had a trading volume of 184,581 shares, compared to its average volume of 417,092. The firm has a 50-day moving average price of $537.32 and a 200 day moving average price of $420.81. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $625.00. The stock has a market capitalization of $16.62 billion, a price-to-earnings ratio of 41.27, a PEG ratio of 2.67 and a beta of 1.42.

Medpace (NASDAQ:MEDP – Get Free Report) last issued its earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The firm had revenue of $659.90 million during the quarter, compared to analysts’ expectations of $640.49 million. During the same period last year, the firm posted $3.01 earnings per share. The firm’s revenue for the quarter was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Institutional Trading of Medpace

Hedge funds and other institutional investors have recently modified their holdings of the company. Quent Capital LLC purchased a new position in Medpace in the third quarter valued at about $25,000. Optiver Holding B.V. purchased a new stake in shares of Medpace during the 3rd quarter worth about $27,000. Geneos Wealth Management Inc. lifted its holdings in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares during the last quarter. Brooklyn Investment Group grew its stake in shares of Medpace by 244.8% in the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock valued at $30,000 after buying an additional 71 shares in the last quarter. Finally, Whittier Trust Co. grew its stake in shares of Medpace by 47.3% in the 1st quarter. Whittier Trust Co. now owns 109 shares of the company’s stock valued at $33,000 after buying an additional 35 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Robert W. Baird set a $613.00 target price on Medpace in a report on Friday, October 24th. UBS Group downgraded shares of Medpace from a “neutral” rating to a “sell” rating and lifted their target price for the stock from $300.00 to $305.00 in a research report on Tuesday, July 29th. Cowen reiterated a “sell” rating on shares of Medpace in a research report on Friday, October 24th. Mizuho boosted their target price on shares of Medpace from $575.00 to $655.00 and gave the company an “outperform” rating in a research note on Friday, October 24th. Finally, Jefferies Financial Group raised their target price on Medpace from $400.00 to $450.00 and gave the stock a “hold” rating in a research report on Tuesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have issued a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $487.18.

Read Our Latest Research Report on MEDP

About Medpace

(Get Free Report)

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

See Also